Rxsight, Inc. SEC Filings

RxSight, Inc. reported lower quarterly sales and a wider loss as growth in its premium cataract lens business slowed. For the three months ended March 31, 2026, sales were $30.9 million, down 18.5% from the prior year, mainly from fewer Light Delivery Device (LDD) sales, while Light Adjustable Lens (LAL) revenue was roughly flat.

Gross profit was $23.5 million with a gross margin of 76.1%, helped by a higher mix of LAL sales. Operating expenses rose to $41.3 million, driven by higher selling, general and administrative spending, and the net loss nearly doubled to $15.9 million. RxSight ended the quarter with $217.9 million in cash, cash equivalents and short-term investments and expects to continue operating losses while investing in commercial expansion and R&D.

RxSight, Inc. reported first quarter 2026 sales of $30.9 million, down 18.5% from a year earlier, mainly due to lower Light Delivery Device volumes, while Light Adjustable Lens procedures decreased 0.4% year over year. Gross profit margin improved to 76.1% from 74.8% on a richer lens mix.

Total operating expenses rose to $41.3 million from $39.0 million as the company expanded its global commercial and support teams. Net loss widened to $15.9 million, or $0.38 per share, versus $8.2 million, or $0.20 per share, with adjusted net loss at $7.9 million, or $0.19 per share. Cash, cash equivalents and short-term investments totaled $217.9 million as of March 31, 2026. RxSight reiterated 2026 revenue guidance of $120 to $135 million and gross margin guidance of 70% to 72%, and now expects operating expenses at the high end of its prior $150 to $160 million range.

RxSight, Inc. is holding its 2026 Annual Meeting of Stockholders as a fully virtual event on June 16, 2026 at 8:00 a.m. Pacific Time. Holders of 41,396,609 shares of common stock outstanding as of April 21, 2026 are entitled to vote.

Stockholders will vote on electing three Class II directors to terms ending in 2029, an advisory “Say‑on‑Pay” approval of 2025 executive compensation, and ratification of Ernst & Young LLP as independent registered public accounting firm for 2026. The proxy explains voting methods, quorum, broker non-votes, board committee structure, director independence and 2025 non‑employee director compensation, including cash retainers and time‑based RSU awards.

RxSight, Inc. Chief Operating Officer Ilya Goldshleger exercised stock options to acquire 12,489 shares of common stock at $4.13 per share. Following the transactions, he holds 78,180 shares directly and 1,372 shares indirectly through his spouse, indicating a routine compensation-related equity exercise with no open-market buying or selling disclosed.

RxSight Inc disclosure: The Vanguard Group filed an amended Schedule 13G/A reporting that, after an internal realignment, certain Vanguard subsidiaries will report holdings separately and The Vanguard Group no longer beneficially owns those securities. The filing states amount beneficially owned: 0 shares representing 0% of the class.

The amendment explains the disaggregation is in accordance with SEC Release No. 34-39538 and is signed by Ashley Grim, Head of Global Fund Administration.

RxSight, Inc. filed an amended report to update details about the compensation of its new Chief Financial Officer, Mark Wilterding. The company confirms that, under his employment agreement effective January 11, 2026, his cash sign-on bonus was set at $169,348.10 and paid on March 13, 2026, after payroll deductions and required withholding.

The amendment also corrects the vesting schedule for his stock option. 25% of the shares underlying the option will vest on the first anniversary of January 11, 2026, and the remaining shares will vest in equal monthly installments over the following three years, so that all option shares are fully vested four years from that date, subject to his continued employment and the terms of the option agreement. All other aspects of the original report remain unchanged.

RxSight, Inc. Chief Financial Officer Mark Wilterding reported equity award activity involving restricted stock units and related common stock. On February 28, 2026, 20,441 restricted stock units were exercised into 20,441 shares of common stock at a price of $0.00 per share. To cover tax obligations on this vesting event, 8,068 shares of common stock were disposed of at $7.61 per share through a tax-withholding arrangement rather than an open-market sale. Footnotes state that one eighth of the RSU award vested on February 28, 2026, with additional one-eighth installments scheduled to vest every six months through the end of a four-year period, subject to continued service.

RxSight, Inc. Chief Customer Officer Scott Gaines reported multiple equity transactions. On February 27, 2026, he received a grant of 32,218 restricted stock units (RSUs), each representing one share of common stock, subject to multi‑year service-based vesting. On February 28, 2026, several RSU awards vested and were exercised, resulting in the acquisition of 6,261 shares of common stock at a stated price of $0.00 per share. On the same date, 2,580 shares of common stock were disposed of at $7.61 per share to cover tax withholding obligations. After these transactions, Gaines directly owned 14,848 shares of RxSight common stock.